---
layout: minimal-medicine
title: Eptifibatide
---

# Eptifibatide
### Generic Name
Eptifibatide

### Usage

Eptifibatide is a medication used to prevent blood clots from forming in blood vessels.  Its primary use is in the treatment of acute coronary syndrome (ACS), a condition encompassing unstable angina (chest pain) and non-ST-elevation myocardial infarction (heart attack).  It's used in patients managed medically or undergoing percutaneous coronary intervention (PCI), a procedure to open blocked arteries.  Eptifibatide is also used to treat patients undergoing PCI, which may or may not include the placement of a coronary stent.  Essentially, it helps keep blood flowing freely through the coronary arteries, reducing the risk of further heart attacks or complications during and after PCI.  Note that some uses, like its use in ST-elevation myocardial infarction, are considered off-label, meaning it's used for a condition not specifically listed in the official prescribing information.

### Dosage

Eptifibatide is administered intravenously (IV).  Dosage varies depending on the condition and the patient's renal function.

**Acute Coronary Syndrome (ACS) and ST-Elevation Myocardial Infarction (off-label):**

* A bolus dose of 180 mcg/kg (maximum 22.6 mg), followed by a continuous infusion of 2 mcg/kg/min (maximum 15 mg/hour).
* A second bolus of 180 mcg/kg (maximum 22.6 mg) is given 10 minutes after the first.
* Infusion continues for 18-24 hours after PCI.  Initiation is typically after diagnostic angiography, just before PCI.

**Percutaneous Coronary Intervention (PCI):**

* A bolus dose of 180 mcg/kg (maximum 22.6 mg) immediately before PCI, followed by a continuous infusion of 2 mcg/kg/min (maximum 15 mg/hour).
* A second bolus of 180 mcg/kg (maximum 22.6 mg) is given 10 minutes after the first.
* Infusion continues for 2-24 hours after PCI.

**Renal Impairment:**  For patients with a creatinine clearance (CrCl) below 50 mL/min, the infusion rate is reduced to 1 mcg/kg/min (maximum 7.5 mg/hour).  Eptifibatide is contraindicated in patients with end-stage renal disease requiring dialysis.

**Pediatric Dosage:**  The safety and effectiveness of eptifibatide in children have not been established.


### Side Effects

Common side effects include bleeding (often the most significant risk), and hypotension (low blood pressure).

Less common, but potentially serious, side effects include:

* Thrombocytopenia (low platelet count), which can lead to increased bleeding risk.  This can be both immune-mediated (allergic reaction) and non-immune-mediated.
* Injection site reactions.
* Allergic reactions, including anaphylaxis (a severe, life-threatening allergic reaction).
* Cerebrovascular accident (stroke)
* Gastrointestinal, intracranial, and pulmonary hemorrhage (bleeding).


If you experience any side effects, particularly bleeding or severe allergic reactions, contact your doctor or seek immediate medical attention.

### How it Works

Eptifibatide works by blocking the activity of a protein called GP IIb/IIIa on the surface of platelets (blood cells involved in clotting).  By blocking GP IIb/IIIa, eptifibatide prevents platelets from sticking together and forming clots. This action reduces the risk of blood clots blocking blood vessels in the heart, a major cause of heart attacks.

### Precautions

* **Contraindications:** Eptifibatide should not be used in patients with a history of active bleeding, bleeding disorders, recent stroke (hemorrhagic or ischemic), uncontrolled high blood pressure, recent major surgery, current use of other GP IIb/IIIa inhibitors, end-stage renal disease, significantly impaired liver function, or thrombocytopenia (low platelet count).
* **Interactions:** Use with other anticoagulants (blood thinners), antiplatelet drugs, or thrombolytic agents (clot-busters) increases the risk of bleeding.
* **Pregnancy and Breastfeeding:** Eptifibatide is categorized as pregnancy category B.  It's unknown if eptifibatide is excreted in breast milk; caution is advised during breastfeeding.
* **Renal Impairment:** Dosage adjustments are necessary for patients with reduced kidney function.
* **Older Adults:**  Older adults may be at increased risk of bleeding.
* **Surgery:** Eptifibatide should be discontinued several hours before surgery.


### FAQs

* **Q: How long does it take for Eptifibatide to work?** A: The effects of eptifibatide begin soon after administration, but the full therapeutic effect develops over time.

* **Q: How long will I need to take Eptifibatide?** A: Eptifibatide is typically given only during a hospital stay, as an infusion, and is not usually taken long term.  The duration of treatment depends on the reason for its use and your response to it.

* **Q: What should I do if I miss a dose?** A: Eptifibatide is administered intravenously in a hospital setting;  missed doses should be addressed with healthcare professionals.

* **Q: How should I store Eptifibatide?** A:  Eptifibatide is administered in a hospital setting and is not typically stored at home.

* **Q: Can I drink alcohol while taking Eptifibatide?** A: Alcohol can increase the risk of bleeding, so it should be avoided while on eptifibatide.  Talk to your doctor.

* **Q: Are there any specific foods I need to avoid?** A: There are no specific foods to avoid.  A healthy and balanced diet is recommended.


**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Always consult with a healthcare professional before starting or stopping any medication, including eptifibatide.  They can assess your individual health status and advise you on the appropriate use and potential risks.
